Fingolimod Reduces Alzheimer’s Disease Pathological Features in Mouse Model

Fingolimod Reduces Alzheimer’s Disease Pathological Features in Mouse Model
Researchers tested the effects of fingolimod, an approved treatment for multiple sclerosis shown to have anti-inflammatory properties, in a mouse model of Alzheimer’s disease (AD). The drug reduced the density of pathological plaques and decreased the number of pro-inflammatory cells in in vivo disease models, suggesting a potential therapeutic role for Alzheimer's. The research paper, “Fingolimod modulates multiple neuroinflammatory markers in a mouse model of Alzheimer’s disease,” was published in Scientific Reports. Plaque deposits of insoluble, aggregated amyloid β (Aβ) peptide is one of the most important neuropathological hallmarks of Alzh
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *